宫颈癌放疗前卵巢移位:功能结局与适宜剂量约束
该回顾性分析纳入118例接受根治性子宫切除及卵巢移位后盆腔照射的宫颈癌患者,其中105例接受调强放疗(IMRT)并对卵巢限量。105例中41例(39.0%)保留正常卵巢功能,卵巢较低侧最大剂量截断值为9.985Gy、平均剂量截断值为5.32Gy,适宜剂量体积约束为V5.5<29.65%;年龄≤38岁(P=0.001)是卵巢功能的独立预测因素。
要点
- IMRT下卵巢限量后39.0%(41/105)患者保留正常卵巢功能。
- 卵巢最大剂量<9.985Gy、平均剂量<5.32Gy、V5.5<29.65%可能更好预防卵巢功能障碍。
- 年龄≤38岁(P=0.001)是卵巢功能的独立预测因素,单侧或双侧限量未见明显影响。
核心结论
- 使用IMRT时,对卵巢照射剂量尽可能低即可保留卵巢功能,无论单侧还是双侧限量。
研究设计与样本
- 回顾性分析2012年4月至2017年7月118例接受根治性子宫切除及卵巢移位后盆腔照射的宫颈癌患者,其中105例接受IMRT并对卵巢限量。
主要发现
- 105例接受IMRT并卵巢限量的患者中41例(39.0%)保留正常卵巢功能。
- 卵巢较低侧最大剂量截断值为9.985Gy,平均剂量截断值为5.32Gy。
- 年龄≤38岁(P=0.001)是卵巢功能的独立预测因素,限量卵巢侧数被排除。
关键数值与推荐
- 卵巢适宜剂量体积约束为V5.5<29.65%。
- 卵巢最大剂量<9.985Gy、平均剂量<5.32Gy可能更好预防卵巢功能障碍。
临床怎么用
- 宫颈癌患者放疗前卵巢移位后行IMRT时,应尽可能降低卵巢剂量,可参考最大剂量<9.985Gy、平均剂量<5.32Gy、V5.5<29.65%进行限量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The data regarding a transposed ovary in intensity-modulated radiotherapy (IMRT) are not sufficient. Here we aim to investigate the adequate dose constraint of ovarian transposition before radiotherapy in cervical cancer patients. METHODS: This was a retrospective analysis of 118 patients with cervical cancer who received a radical hysterectomy and ovarian transposition before pelvic irradiation from April 2012 to July 2017. A total of 105 patients underwent IMRT with a limited radiation dose to the ovaries; 48 of these patients received unilateral ovary limitation, while 57 received bilateral ovary limitations. Patient follow up regarding sex hormone levels (estrogen [E2], follicle stimulating hormone [FSH]) and menopausal symptoms was completed one year after their radiation therapy. RESULTS: A total of 41 out of 105 patients (39.0%) who underwent IMRT with a limited radiation dose to the ovaries preserved their normal ovarian function. The cutoff dose of comparatively lower side ovarian maximum dose was 9.985Gy and the cutoff of mean dose was 5.32Gy. The optimal dose-volume constrains to ovaries was V5.5 < 29.65%. Age ≤ 38 (P = 0.001) was an independent predictors of ovarian function, while limited ovarian side numbers were excluded. CONCLUSION: Using IMRT, preservation of ovarian function was possible when the limited dose was as low as possible to the ovaries regardless of bilateral or unilateral limitation to the ovaries. The ovarian maximum dose of less than 9.985Gy, the mean dose less than 5.32Gy and V5.5 < 29.65% could be better at preventing ovarian dysfunction. Patients younger than 38 years old were more likely to keep normal ovarian function while limited ovarian side numbers did not appear to exert an obvious effect.
引用
- Yin L, Lu S, Zhu J, et al. Ovarian transposition before radiotherapy in cervical cancer patients: functional outcome and the adequate dose constraint. Radiat Oncol. 2019. PMID: 31182114. doi:10.1186/s13014-019-1312-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。